Computational modelling and invitro evaluation identified natural product - Z218 as a novel Janus Kinase-2 (JAK2) inhibitor to combat Beta Thalassemia.
Sign Up to like & getrecommendations! Published in 2023 at "Biotechnology and applied biochemistry"
DOI: 10.1002/bab.2459
Abstract: Aberrant activity of Janus kinase 2 (JAK2) is a known driver of several myeloproliferative disorders, including polycythemia Vera, and Thalassemia. Several inhibitors have been proposed to inhibit JAK2 activity in order to control the disease… read more here.
Keywords: kinase jak2; kinase; jak2; natural product ... See more keywords
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18207
Abstract: Fedratinib, an oral Janus kinase‐2 (JAK2) inhibitor, is approved for patients with myelofibrosis (MF) and platelet counts ≥50 × 109/l, based on outcomes from the phase 3, placebo‐controlled JAKARTA trial in JAK‐inhibitor‐naïve MF, and the phase 2,… read more here.
Keywords: kinase jak2; patients myelofibrosis; inhibitor; platelet ... See more keywords